Adaptive Biotechnologies raised 2026 revenue guidance for its minimal residual disease business after strong Q1 growth in ClonoSeq-based testing. Adaptive now expects MRD revenue of $260 million–$270 million for full-year 2026, building on 53% year-over-year MRD segment growth in Q1. The company said MRD accounted for 95% of Q1 revenue and that ClonoSeq delivered a record number of tests, with volumes rising across reimbursed indications, led by diffuse large B-cell lymphoma. Adaptive also highlighted distribution dynamics, including community-based testing growth and an average selling price of $1,360 in the quarter. It further pointed to a growing bookings backlog of approximately $254 million. For MRD-focused diagnostics, the update suggests ongoing payer and clinician adoption of immune-sequencing workflows and supports continued scaling in both clinical and MRD pharma services.